Key Position Statements

Public Policy Library

AST Employee Leave &
Organ Donation Program

AST Newsletter Articles

AST Homepage


WASHINGTON
REPRESENTATIVE:

Bill Applegate
Director of
Government Relations

Armstrong Teasdale LLP
1747 Pennsylvania Avenue, NW
Suite 300
Washington, DC 20006-4604
P: 202- 454-2864
F: 202-
393-0363
wapplegate@armstrongteasdale.com

American Society
of Transplantation
17000 Commerce Pkwy.
Mt. Laurel, NJ 08054
P: 856-439-9986
F: 856-439-9982
ast@ahint.com


 

 

 

 

 

 

 

 

  PUBLIC POLICY LIBRARY
   

American Society of Transplant Physicians
 

Public Policy Library Document

Washington Round-Up

April 10, 1998

Research!America Releases Poll on Medical Research

Research!America recently released the findings from polls conducted in six states that show that a "majority of citizens support doubling funding of government-sponsored medical research over the next five years and see increased taxes on cigarettes as a way to pay for it." The states that were polled included Connecticut, Michigan, Virginia, Washington, and West Virginia.

D'Amato Proposes Tax Credit Aid to Medical Schools & Teaching Hospitals

Senator Alfonse D'Amato (R-NY) recently introduced legislation that would "provide medical innovation tax credit for companies that conduct clinical testing research activities at U.S. medical schools and teaching hospitals." The "Medical Innovation Tax Credit Act of 1998," S. 1885, is modeled after California law that encourages pharmaceutical and biotechnology companies to expand their research activities at medical schools and teaching hospitals in the state.

The bill would establish "an incremental 20% tax credit that would be available to companies that conduct clinical testing research at certain academic institutions including medical schools and teaching hospitals owned or affiliated with an institution of higher education."

Kidney Disease Among Lowest Funded Disease at NIH

Recent statistics from the National Institutes of Health (NIH) show that compared to the other leading diseases receiving research dollars at the NIH, kidney disease is among the lowest. Compared to major NIH research funded diseases including hematology, arthritis, lung, urology, cardiovascular, and digestive, kidney disease received only $208 million across the NIH campus, $16 million less than arthritis for 1998.

Specter Amendment Tabled

On Thursday, April 2, 1998, the U.S. Senate voted 57 to 41 to table Senator Arlen Specter's (R-PA) amendment to the FY 1999 budget resolution to provide a $2 billion increase for the NIH in FY 1999. Funding from this proposed NIH increase was to come from an 0.4% across-the-board-cut of the other budget functions, including defense.

New NIH Training Programs

The National Institutes of Health (NIH) recently announced three new training programs to boost the number of well-trained clinical researchers in the U.S. Among the programs is a Clinical Research Curriculum Award (CRCA) which the National Heart, Lung, and Blood Institute (NHLBI) will administer. This K 30 grant is for educational and research institutions and will support the development or improvement of core courses of in-depth instruction in the fundamental skills, methodology, theories, and conceptualizations necessary for the well-trained, independent, clinical researcher. The average annual award is expected to be $200,000, with approximately 20 awards to be made in FY 1999. Applications are due by October 1, 1998.

Managed Care Debate Continues

On Tuesday, March 31, 1998, Congressional Democrats released their managed care legislation that focuses in more on "patients than providers and would give patients more leverage in dealing with insurers," according to bill sponsors. In their managed care bill, Democrats would:

  • allow patients to have greater access to specialists, even if those specialists are not in patient's pre-approved health plan, as well as greater access to emergency care without prior approval from insurance companies;
  • allow individuals to take legal action against insurance companies for damages under state malpractice laws;
  • permit patients to enroll in clinical trials as long as the trials are the only hope for overcoming a life threatening illness;
  • mandate coverage for drugs not included in health plans; and
  • provide patients with a greater opportunity to appeal denials for coverage made by insurance companies.

Contentious Tobacco Debate Continues

As you may be aware, many groups within the medical research community have been aggressively supporting tobacco bills which seek to generate additional funds for research at the National Institutes of Health (NIH). The following information explains and outlines the current status of this important debate.

Prior to adjourning for a two week spring recess, the Senate approved its version of the 1999 budget resolution (S Con Res 86) - a nonbinding document that sets the parameters for appropriators and tax writers to craft binding legislation. During consideration, the Senate rejected an amendment by Senator Kent Conrad (D-ND) to codify the national tobacco settlement and dedicate resulting revenues to education and health programs to discourage smoking among teenagers. Budget Chairman Pete Domenici (R-NM) opposed Senator Conrad's amendment, arguing that the billions of dollars in tobacco revenues should be used to save the Medicare program.

At the same time as the Senate was considering the FY 1999 budget resolution, the Senate Commerce Committee approved Chairman John McCain's (R-NM) tobacco bill, S. 1414, the National Tobacco Policy & Youth Smoking Protection Act . The bill was approved by a vote of 19-1, including a "Yes" vote by Senate Majority Leader Trent Lott (R-MS). Following Committee approval of the bill, a White House Senior Domestic Advisor said that tobacco legislation is the President's number one priority and that the White House will push for approval of the Commerce Committee bill. With regard to research, the legislation would provide $2.5 billion per year to the NIH for research in support of epidemiological, behavioral, and social science research (including the training of researchers) related to the treatment and prevention of diseases associated with tobacco. S. 1414 would also require tobacco companies to pay $506 billion over 25 years for legal damages and anti-smoking, education and research programs. In addition, the bill would raise cigarette prices $1.10 a pack over five years and grant authority to the FDA to regulate and, with Congress' approval, ban nicotine.

Also prior to adjourning for spring recess, Senators Tom Harkin (D-IA) and John Chafee (R-RI) introduced S. 1889, the Kids Deserve Freedom from Tobacco Act. With regard to research, S. 1889 would establish a national fund for health research and provide an additional $3.225 billion per year to NIH. In addition, a task force would award $600 million of the funds for the prevention and cessation of tobacco use.

On Wednesday, April 8, 1998, RJR Nabisco Chief Executive Officer, Steven Gladstone, spoke to an audience at the National Press Club to discuss legislation to implement the national tobacco settlement. During his address, Gladstone strongly opposed the current tobacco bills pending in Congress and said that the industry is interested in combating youth smoking - but not in declaring bankruptcy. Mr. Gladstone also said that the current legislative vehicles addressing the tobacco settlement are not acceptable and that the tobacco industry is not interested in cooperating with or supporting such initiatives.

 

Back to top
Return to Public Policy Library menu